Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future-Reference-Cited by-同舟云学术

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future

Published:2020-02-29 Issue:1 Volume:18 Page:1-9
ISSN:1738-1088
Container-title:Clinical Psychopharmacology and Neuroscience
language:en
Short-container-title:Clin Psychopharmacol Neurosci

Author:

Fabbri Chiara¹^ORCID,Serretti Alessandro²^ORCID

Affiliation:

1. Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom

2. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

Publisher

Korean College of Neuropsychopharmacology

Subject

Pharmacology (medical),Behavioral Neuroscience,Psychiatry and Mental health

Link

http://pdf.medrang.co.kr/CPN2/2020/018/cpn018-01-01.pdf

Reference45 articles.

1. National Human Genome Research Institute. DNA sequencing costs: data [Internet]. Bethesda: National Institute of Health; 2017 [cited at 2017 Nov 27]. Available from: https://www.genome.gov/sequencingcostsdata/.

2. Prevalence of treatment-resistant depression in primary care: cross-sectional data

3. Treatment resistant depression: methodological overview and operational criteria

4. A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013

5. Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response;Journal of Affective Disorders;2024-10

2. Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study;Pharmacopsychiatry;2024-06-25

3. The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia;Molecular Psychiatry;2023-12-20

4. The role of pharmacogenetics in the treatment of major depressive disorder: a critical review;Frontiers in Psychiatry;2023-11-10

5. Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores;Journal of Community Genetics;2022-12-19